LB-2101

N/A

Report date: 2026/04/20 14:11:45

Base Information

Drug NameLB-2101

Drug Alias NameLB-2101

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionWnt signalling pathway inhibitorsGlypican-3 inhibitors

TargetsGlypican-3

Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungCarcinoma, Hepatocellular

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesNanjing Legend Biotechnology Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesNanjing Legend Biotechnology Co Ltd

Inactive CompaniesN/A

Active IndicationsCarcinoma, Non-Small-Cell LungCarcinoma, Hepatocellular

Inactive IndicationsN/A

Other Information

ATC CodeN/A